1. Home
  2. CASI

as of 02-17-2026 4:00pm EST

$0.82
$0.03
-3.06%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Founded: 1991 Country:
China
China
Employees: N/A City: N/A
Market Cap: 19.7M IPO Year: 1996
Target Price: $4.00 AVG Volume (30 days): 26.1K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.98 EPS Growth: N/A
52 Week Low/High: $0.74 - $3.09 Next Earning Date: 03-30-2026
Revenue: $26,846,000 Revenue Growth: 21.72%
Revenue Growth (this year): -51.78% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered CASI Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 21 hours ago

AI Recommendation

hold
Model Accuracy: 74.36%
74.36%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: